Key facts
- Mastatest’s last known valuation is $9.2M (Jul 2022).
- It has raised $3.1M; the latest was Later Stage VC ($1.1M) in Dec 2025.
- Notable investors include Icehouse Ventures, K1W1, Enterprise Angels, New Zealand Growth Capital Partners, Artemis Capital (Auckland) — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Mastatest
- ·The full record, as it builds
Funding rounds
No funding rounds for Mastatest are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mastatest
Operator of a diagnostic testing platform intended to offer a point-of-care bovine mastitis diagnostic test for cows. The company's platform helps identify bacterial infections and also provides outcomes related to antibiotic sensitivities of commonly used mastitis products, which is an essential tool for cost-effective antimicrobial usage and prescription practices at the farm level, enabling clients to get rapid processing test samples that are reproducible and convenient.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Dunedin, New Zealand
- Founded
- 2013
- Employees
- 18
- Website
- mastatest.com/
- Ownership
- Privately Held (backing)
Mastatest doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mastatest shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mastatest in its N-PORT filings yet. We sweep new filings monthly.